JP2003502388A5 - - Google Patents

Download PDF

Info

Publication number
JP2003502388A5
JP2003502388A5 JP2001504415A JP2001504415A JP2003502388A5 JP 2003502388 A5 JP2003502388 A5 JP 2003502388A5 JP 2001504415 A JP2001504415 A JP 2001504415A JP 2001504415 A JP2001504415 A JP 2001504415A JP 2003502388 A5 JP2003502388 A5 JP 2003502388A5
Authority
JP
Japan
Prior art keywords
mla
lipid
composition
antigen
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001504415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003502388A (ja
Filing date
Publication date
Priority claimed from US09/338,182 external-priority patent/US6491919B2/en
Application filed filed Critical
Publication of JP2003502388A publication Critical patent/JP2003502388A/ja
Publication of JP2003502388A5 publication Critical patent/JP2003502388A5/ja
Pending legal-status Critical Current

Links

JP2001504415A 1999-06-22 2000-06-14 モノホスホリルリピドａの水性免疫学的アジュバント組成物 Pending JP2003502388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/338,182 US6491919B2 (en) 1997-04-01 1999-06-22 Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US09/338,182 1999-06-22
PCT/US2000/016384 WO2000078353A2 (en) 1999-06-22 2000-06-14 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (2)

Publication Number Publication Date
JP2003502388A JP2003502388A (ja) 2003-01-21
JP2003502388A5 true JP2003502388A5 (https=) 2007-08-02

Family

ID=23323749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001504415A Pending JP2003502388A (ja) 1999-06-22 2000-06-14 モノホスホリルリピドａの水性免疫学的アジュバント組成物

Country Status (9)

Country Link
US (1) US6491919B2 (https=)
EP (1) EP1194166B1 (https=)
JP (1) JP2003502388A (https=)
AT (1) ATE381344T1 (https=)
AU (1) AU775942B2 (https=)
CA (1) CA2376829A1 (https=)
DE (1) DE60037514T2 (https=)
ES (1) ES2296629T3 (https=)
WO (1) WO2000078353A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
EP2000144A1 (en) * 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US7848801B2 (en) 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
AU2009248810B2 (en) * 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
BRPI1014031A2 (pt) * 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3069729A1 (en) 2015-03-17 2016-09-21 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
WO2022251455A1 (en) * 2021-05-27 2022-12-01 Revelation Biosciences, Inc. Methods of treating or preventing allergies and chronic nasal congestion
WO2025058011A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 経鼻投与用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
ATE372783T1 (de) * 1993-01-22 2007-09-15 Sloan Kettering Inst Cancer Gangliosid-klh-konjugatimpfstoffe mit qs-21 zur verzögerung des wiederauftretens eines melanoms
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP5019494B2 (ja) モノホスホリルリピドａの水性免疫アジュバント組成物
JP2003502388A5 (https=)
ES2296629T3 (es) Composiciones adyuvantes inmunologicas acuosas de monofosforil-lipido a.
KR100682154B1 (ko) 아쥬번트 조성물 및 그의 사용방법
JP4743928B2 (ja) 処方物
AU4094301A (en) Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
EP1150713B1 (en) Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
WO2010033812A1 (en) Compositions and methods for treating hepatitis a.
US20040191214A1 (en) Nucleoside vaccine adjuvants
AU2916302A (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid
HK1026613B (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
MXPA99009052A (en) Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
FR2692149A1 (fr) Composition adjuvante de l'immunité humorale et à médiation cellulaire n'induisant pas de réponse vis-à-vis de déterminants auto-antigéniques.